Imagion Biosystems announces on ASX that it has received a total of $18,460.05 for the exercise of 363,201 Listed Options exercisable at 5 cents, expiring on 26 November 2021, and 10,000 Listed Options exercisable at 3 cents, expiring at 28 April 2023.
Please click to review the full announcement at ASX.
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance